

Nasal vaccine, new solution for global health

Seeking for:

1. Investors for capital injection (7MUSD; 2020)
2. Out-license partnering with pharma/vaccine manufacturer

A) Where we start from and what we can offer :

The founders of HanaVax; from Univ of Tokyo; have successfully developed cutting edge platform technologies for developing novel vaccines to prevent diseases that still pose challenges to human health. Our strength lies in our ability to stimulate protective mucosal as well as systemic immunity. This establishes two levels of defense, in contrast to most injected vaccines that stimulate only systemic, blood-based immunity.

Our novel delivery formulations retain the antigens on respiratory mucosal surfaces long time and initiate antigen-specific immune responses via the mucosal immune system. This results in more effective uptake, processing and presentation of the antigens by immune cells (e.g., nasal dendritic cells), which in turn results in strong antigen-specific T cell and B cell immune responses at both mucosal surfaces and in the systemic circulation for the protective immunity. This vaccination method has been shown to induce protective immunity against pneumococcal pneumonia in nonhuman primates.

B) Business Focus:

Develop nasal vaccine against infectious diseases is our company business focus. Our platform technology enables protein antigen of interest capsulated in cationic charged nanogel. Spray into nasal cavity and effectively induce secretion of IgA; which can effectively prevent invasion of pathogen at mucosal surface (i.e. respiratory tracts) and to reduce host-to-host transmission.

HanaVax is pushing forward development of a human pneumococcal nasal vaccine to prevent pneumonia, sepsis and otitis media. The specific antigens have been selected in collaboration research partners in the University of Alabama at Birmingham to provide nearly complete coverage of all forms of disease-causing pneumococcus.

Pneumococcal vaccine is our lead product; having potential entering market which has already exceeded 7B USD. Research is ongoing to adapt HanaVax's proprietary mucosal delivery system to other pathogens. Other pipelines include HPV therapeutic vaccine, HSV vaccine, Non-typeable Haemophilus influenzae (NTHi) vaccine, RSV vaccine and TB vaccine. Most of the listed pipelines are candidate for unmet needs medicine and having potential to become blockbuster (>1B USD).

HanaVax Inc.

HQ : Tokyo, Japan

CEO & President : Ng Pohsing

Contact: nps@hanavax.co.jp

Business : Developing nasal vaccine for infectious diseases

www.hanavax.co.jp

Learn more

